Usa India city Mumbai hospital covid-19 patient Usa India city Mumbai

Specialty products ramp-up key to Sun Pharma's fortunes

Reading now: 615
www.livemint.com

MUMBAI : MUMBAI: Dragging on Sun Pharmaceutical's otherwise decent Q4 results was the impact of cost increases.

While the pharmaceutical major's specialty business has picked up, a further squeeze on margins may dampen investor sentiment for the stock in coming quarters.

The stock was up 1.8% at ₹458.50 per share in trade on Thursday. One key parameter that the Street was looking out for was the ramp-up in its specialty division.

Ilumya, among its key branded formulation products, logged sales of about $94 million in FY20, higher than estimates and therefore quite encouraging.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA